- Home
- ATOS vs MAPS Comparison
ATOS vs MAPS Comparison
Compare ATOS & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- MAPS
- Stock Information
- Founded
- ATOS 2009
- MAPS 2008
- Country
- ATOS United States
- MAPS United States
- Employees
- ATOS N/A
- MAPS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- MAPS Computer Software: Prepackaged Software
- Sector
- ATOS Health Care
- MAPS Technology
- Exchange
- ATOS Nasdaq
- MAPS Nasdaq
- Market Cap
- ATOS 114.5M
- MAPS 134.9M
- IPO Year
- ATOS 2012
- MAPS N/A
- Fundamental
- Price
- ATOS $0.80
- MAPS $1.39
- Analyst Decision
- ATOS Strong Buy
- MAPS Strong Buy
- Analyst Count
- ATOS 3
- MAPS 1
- Target Price
- ATOS $7.00
- MAPS $2.61
- AVG Volume (30 Days)
- ATOS 678.1K
- MAPS 1.4M
- Earning Date
- ATOS 03-31-2025
- MAPS 11-12-2024
- Dividend Yield
- ATOS N/A
- MAPS N/A
- EPS Growth
- ATOS N/A
- MAPS N/A
- EPS
- ATOS N/A
- MAPS N/A
- Revenue
- ATOS N/A
- MAPS $183,311,000.00
- Revenue This Year
- ATOS N/A
- MAPS N/A
- Revenue Next Year
- ATOS N/A
- MAPS $5.99
- P/E Ratio
- ATOS N/A
- MAPS N/A
- Revenue Growth
- ATOS N/A
- MAPS N/A
- 52 Week Low
- ATOS $0.72
- MAPS $0.70
- 52 Week High
- ATOS $2.31
- MAPS $1.65
- Technical
- Relative Strength Index (RSI)
- ATOS 41.00
- MAPS 51.53
- Support Level
- ATOS $0.79
- MAPS $1.31
- Resistance Level
- ATOS $0.89
- MAPS $1.47
- Average True Range (ATR)
- ATOS 0.05
- MAPS 0.08
- MACD
- ATOS 0.01
- MAPS 0.00
- Stochastic Oscillator
- ATOS 25.14
- MAPS 55.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.